[1] Johnson KM, Lange JV, Webb PA, et al. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet, 1977; 1, 569-71. http://www.sciencedirect.com/science/article/pii/S0140673677920001
[2] Kuhn JH, Bao Y, Bavari S, et al. Virus nomenclature below the species level:a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol, 2013; 158, 1425-32. doi:  10.1007/s00705-012-1594-2
[3] Lawrence P, Danet N, Reynard O, et al. Human transmission of Ebola virus. Curr Opin Virol, 2017; 22, 51-8. doi:  10.1016/j.coviro.2016.11.013
[4] Dye C. Ebola virus disease in West Africa——the first 9 months. N Engl J Med, 2015; 372, 188-9. doi:  10.1056/NEJMc1413884
[5] Kaner J, Schaack S. Understanding Ebola:the 2014 epidemic. Global Health, 2016; 12, 53. doi:  10.1186/s12992-016-0194-4
[6] Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet, 1980; 2, 1294-5. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=0520071204591347
[7] Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology, 2006; 346, 394-401. doi:  10.1016/j.virol.2005.10.042
[8] Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines:implications for regulatory approval by the animal rule. Nat Rev Microbiol, 2009; 7, 393-400. doi:  10.1038/nrmicro2129
[9] Ye L, Yang C. Development of vaccines for prevention of Ebola virus infection. Microbes Infect, 2015; 17, 98-108. doi:  10.1016/j.micinf.2014.12.004
[10] Yang L, Li J, Gao GF, et al. Overview of Ebola virus vaccine. Sheng Wu Gong Cheng Xue Bao, 2015; 31, 1-23. http://d.old.wanfangdata.com.cn/Periodical/swgcxb201501001
[11] Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol, 2004; 78, 5458-65. doi:  10.1128/JVI.78.10.5458-5465.2004
[12] Volchkov VE, Volchkova VA, Slenczka W, et al. Release of viral glycoproteins during Ebola virus infection. Virology, 1998; 245, 110-9. doi:  10.1006/viro.1998.9143
[13] Dolnik O, Kolesnikova L, Becker S. Filoviruses:Interactions with the host cell. Cell Mol Life Sci, 2008; 65, 756-76. doi:  10.1007/s00018-007-7406-2
[14] Falasca L, Agrati C, Petrosillo N, et al. Molecular mechanisms of Ebola virus pathogenesis:focus on cell death. Cell Death Differ, 2015; 22, 1250-9. doi:  10.1038/cdd.2015.67
[15] Konduru K, Bradfute SB, Jacques J, et al. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine, 2011; 29, 2968-77. doi:  10.1016/j.vaccine.2011.01.113
[16] Zhang X, Yang R, Wang J, et al. Eukaryotic Expression and Immunogenic Research of Recombination Ebola Virus Membrane Protein Gp-Fc. Chinese Journal of Virology, 2016; 32, 8-13. (In Chinese)
[17] Yang R, Zhang X, Wang J, et al. Construction and Immunogenic Research of a Recombination Zaire Ebola Virus Lipoprotein GDP-FCC DNA Vaccine. Chinese Journal of Virology, 2017; 33, 186-90. (In Chinese) http://jtp.cnki.net/bilingual/detail/html/BDXB201702010
[18] Chen Q, Tang K, Zhang X, et al. Establishment of pseudovirus infection mouse models for in vivo pharmacodynamics evaluation of filovirus entry inhibitors. Acta Pharm Sin B, 2018; 8, 200-8. doi:  10.1016/j.apsb.2017.08.003
[19] Wang LL, Chen Q, Zhou LN, et al. Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro. Acta Pharmaceutica Sinica, 2015; 50, 1545-50. (In Chinese) http://www.ncbi.nlm.nih.gov/pubmed/27169275
[20] He J, Choe S, Walker R, et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol, 1995; 69, 6705-11. http://www.ncbi.nlm.nih.gov/pubmed/7474080
[21] Xie Q, Xinyong G, Xianjin C, et al. PEI/DNA formation affects transient gene expression in suspension Chinese hamster ovary cells via a one-step transfection process. Cytotechnology, 2013; 65, 263-71. doi:  10.1007/s10616-012-9483-9
[22] Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc, 2009; 4, 495-505. doi:  10.1038/nprot.2009.22
[23] Hoenen T, Groseth A, de Kok-Mercado F, et al. Minigenomes, transcription and replication competent virus-like particles and beyond:reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res, 2011; 91, 195-208. doi:  10.1016/j.antiviral.2011.06.003
[24] Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature, 2003; 424, 681-4. doi:  10.1038/nature01876
[25] Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med, 2014; 20, 1126-9. doi:  10.1038/nm.3702
[26] Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med, 2005; 11, 786-90. doi:  10.1038/nm1258
[27] Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, 2015; 386, 857-66. doi:  10.1016/S0140-6736(15)61117-5
[28] Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog, 2007; 3, e2. doi:  10.1371/journal.ppat.0030002
[29] Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol, 2008; 82, 5664-8. doi:  10.1128/JVI.00456-08
[30] Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease:final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet, 2017; 389, 505-18. doi:  10.1016/S0140-6736(16)32621-6